Sunitinib
FDA Approved
Description
Sunitinib is a tyrosine kinase inhibitor used in the treatment of renal cell carcinoma. It works by blocking several protein kinases, preventing tumor growth and angiogenesis.
Indications & Therapeutic Use
Renal cell carcinoma, gastrointestinal stromal tumor, pancreatic neuroendocrine tumors
Linked Diseases:
renal cell carcinoma
C64D002292
Global Availability (5 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Sunitinib
| Generic Name | Sunitinib |
| Brands | 1 brand available |
| Active Ingredient | Sunitinib malate |
| Drug Class | Renal cell carcinoma |
| Manufacturer | Pfizer |
| Dosage Forms | Oral capsule |
| Medical Code | L01XE04 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Reg. Status | FDA Approved |
| Countries | 5 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations6 Validated Nodes